Compare ADMA Biologics Inc (ADMA) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Texas Instruments Incorporated — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while Texas Instruments Incorporated trades at $304 (market cap $266.93B). The key difference: Texas Instruments Incorporated is far larger — about 125.3× ADMA Biologics Inc's market cap, and Texas Instruments Incorporated pays a 1.94% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | TXN | |
|---|---|---|
Market Cap | $2.13B | $266.93B |
Sector | Health | Technology |
52-Week High | $20.38 | $332.35 |
52-Week Low | $7.60 | $153.33 |
Enterprise Value | $2.20B | $275.88B |
Dividend Yield | — | 1.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Texas Instruments (TXN) trades at $303.50, up 3.56% over 24 hours, with a bullish technical signal and strong profitability metrics including a 29.11% net income margin. Recent Q1 2026 earnings beat expectations, and the company announced a CFO transition with Julie Knecht set to succeed Rafael Lizardi in August 2026. Cash flow trends show improving operational performance, with 2025 operating cash flow at $7.15 billion.
The outlook remains positive with analyst consensus pointing to a $310.95 price target and 47.69% buy ratings. Key risks include elevated valuation ratios like a P/E of 51.88 and rising debt-to-asset ratio, now at 40.61% for 2025. Growth is supported by AI-driven demand in data centers, but investors should monitor execution on sequential revenue guidance and competitive pressures in the semiconductor space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
